Coromandel International Limited
Quality (47/100) does the heavy lifting; valuation (11/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Coromandel International Limited a Sell, scoring 33/100 on our blended model. On 29.9x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 24% below its 52-week high of ₹2,678.22 and 17% above the low of ₹1,743.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,328.63 implies about 14% upside across 8 analysts. It clears 6 of 13 investability checks, with durability 47, valuation 21 and momentum 46 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹989.5.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-23.92% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell33Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 15.6%
- Pass: Low debt (D/E < 0.5): 0.11x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 20%
- Fail: Earnings growing: -76%
- Fail: Net margin ≥ 10%: 6.2%
- Pass: Current ratio > 1.5: 1.51
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.11
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter59.5%
- Institutions23.5%
- Public & other16.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 5.11.
Opportunities
- Revenue growing (20% YoY).
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~39% above our estimated fair value.
About Coromandel International Limited
Coromandel International Limited operates two business segments—Nutrient and Other Allied Business, and Crop Protection—offering fertilizers, bio-products, specialty nutrients, and crop protection products to agricultural markets in India and internationally. Its product portfolio includes fertilizers like GroPlus Pro Mg and Gromor Urea Super Phosphate, bio-products such as MycoRitz and Grovibe, and specialty nutrients including Pixibud, Pixigrow, Nano Urea, Areca Shakti, and Coffee Bliss, alongside crop protection products like Caveco, Marvex, and Prachand.
Coromandel International Limited — frequently asked questions
Is Coromandel International Limited a buy, hold or sell?
StocksWizard currently rates Coromandel International Limited (COROMANDEL) a Sell, based on a blended score of 33/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Coromandel International Limited's fair value?
Our blended DCF and relative-valuation model estimates Coromandel International Limited's fair value at about ₹1,236.88, versus a current price of ₹2,037.6 — roughly 39% downside. On that basis the stock looks overvalued by 39%.
Is Coromandel International Limited financially healthy?
Coromandel International Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Coromandel International Limited's share price performed?
Coromandel International Limited is up 3% over three months, and last traded at ₹2,037.6. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.